Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Multiplicom's CF and FMF Dx; Enzymatics' Archer FusionPlex Heme; CHLA's RB1 Test


Multiplicom has launched a next-generation sequencing-based test for cystic fibrosis and plans to launch a test for familial Mediterranean fever in July. The kits will have the CE-IVD marking. Multiplicom has also achieved ISO 13485 accreditation, which certifies the company to design, develop, manufacture, and distribute in vitro molecular diagnostic kits that identify genomic and somatic variants.

Enzymatics has launched its Archer FusionPlex Heme panel, a targeted next-generation sequencing-based assay that detects fusions involving 19 genes associated with hematological malignancies. The assay is based on the company's proprietary anchored multiplex PCR-based enrichment technology.

The Children's Hospital Los Angeles has launched a next-generation sequencing-based retinoblastoma test, RB1 NextGen. The test evaluates germline mutations in the entire RB1 gene.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.